 |
|
Pharmacotherapy of Chronic Fatigue Syndrome
Another Gallant Attempt
Stephen E. Straus, MD
JAMA. 2004;292:1234-1235.
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
As the ability to treat the physical manifestations of many illnesses improves, physicians grapple more seriously with their emotional, social, and symptomatic dimensions. For example, palliative care is now a critical healing art, while oncology begins to contend with the long-term sequelae of the curative regimens for which it has labored so long to craft. Today, quality-of-life instruments and symptom rating scales are essential metrics of health status and outcomes.
Among the illness symptoms that are now addressed in the context of clinical practice and research, fatigue seems the most refractory to measurement and management. Although fatigue is a recognized complication of certain conditions and treatments—advanced cancers and multiple sclerosis, and a consequence of radiation and recombinant interferon therapy—the tools and techniques used to assess and ameliorate fatigue and the comprehension of its pathogenesis are decidedly inferior to those for other prevalent symptoms like pain and . . . [Full Text of this Article]
Author Affiliation: National Center for Complementary and Alternative Medicine, National Institutes of Health, Bethesda, Md.
RELATED ARTICLE
Effect of Galantamine Hydrobromide in Chronic Fatigue Syndrome: A Randomized Controlled Trial
C. V. Russell Blacker, David T. Greenwood, Keith A. Wesnes, Rosamund Wilson, Carol Woodward, Ian Howe, and Tauhid Ali
JAMA. 2004;292(10):1195-1204.
ABSTRACT
| FULL TEXT
|
